The world's largest biotech fund, the iShares Nasdaq Biotech ETF, has had a quiet couple of months. For the last four months, the fund has been consolidating in a tight range between about 285.00 and 303.00. That changed abruptly this week, with prices surging out of that range to hit a high above 320.00.
The pharmaceutical industry's middlemen face a 2017 clampdown.
Dan Collins, Editor in Chief, Modern Trader magazine, discusses how the election results will not change the anticipated rate hike in December.
Hedge fund mogul William Ackman told his investors on Friday that he was confident in his bet on Valeant Pharmaceuticals.
Due to geopolitics, equities are becoming more volatile, causing U.S. stock index futures to fall after a major rally.